Patent US5922304A successfully refreshed from Google Patents.
US5922304A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents
Assignee: Cerevast Medical Inc
•
Filing: 1995-03-09
•
Granted: 1999-07-13
•
Expires: 2015-03-09
Abstract
Abstract Novel gas filled microspheres useful as magnetic resonance imaging (MRI) contrast agents are provided.
Inventors
- 👤 Evan C. Unger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 01:43
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/10; A61K9/127; A61K41/00; A61K41/0028; A61K41/0052; A61K47/00; A61K47/50; A61K47/69; A61K47/6905; A61K47/6911; A61K47/6921; A61K47/6925; A61K49/00; A61K49/06; A61K49/18; A61K49/1806; A61K49/1815; A61K49/1818; A61K49/1821; A61K49/22; A61K49/222; A61K49/223; A61K49/227; A61K9/1277; A61K9/1278; A61K9/48; A61K9/50; A61K9/5005; A61K9/5015; G; G01; G01R; G01R33/00; G01R33/20; G01R33/44; G01R33/48; G01R33/54; G01R33/56; G01R33/5601; A61M; A61M5/00; A61M5/178; A61M5/31; A61M5/3145
Claims Analysis
Total Claims: 45
Claim 1
Independent Claim
84 words
A method of providing an image of an internal region of a patient comprising (i) administering to the patient a gaseous precursor filled microsphere, wherein said microsphere contains substantially no sulfide linkages and consists essentially of one or more lipids, one or more lipids bearing polymers, or combinations thereof, (ii) allowing the gaseous precursor to undergo a phase transition from a liquid to a gas in the patient, and (iii) scanning the patient using magnetic resonance imaging to obtain visible images of said region.
Claim 2
Independent Claim
84 words
A method of providing an image of an internal region of a patient comprising (i) administering to the patient a gaseous precursor filled microsphere, wherein said microsphere contains substantially no sulfide linkages and consists essentially of one or more lipids, one or more lipids bearing polymers, or combinations thereof, (ii) allowing the gaseous precursor to undergo a phase transition from a liquid to a gas in the patient, and (iii) scanning the patient using magnetic resonance imaging to obtain visible images of said region.
Claim 3
Independent Claim
92 words
A method for diagnosing the presence of a diseased tissue or region in a patient comprising (i) administering to the patient a gaseous precursor filled microsphere, wherein said microsphere contains substantially no sulfide linkages and consists essentially of one or more lipids, one or more lipids bearing polymers, or combinations thereof, (ii) allowing the gaseous precursor to undergo a phase transition from a liquid to a gas in the patient, and (iii) scanning the patient using magnetic resonance imaging to obtain visible images of any diseased tissue or region in the patient.
Claim 4
Independent Claim
92 words
A method for diagnosing the presence of a diseased tissue or region in a patient comprising (i) administering to the patient a gaseous precursor filled microsphere, wherein said microsphere contains substantially no sulfide linkages and consists essentially of one or more lipids, one or more lipids bearing polymers, or combinations thereof, (ii) allowing the gaseous precursor to undergo a phase transition from a liquid to a gas in the patient, and (iii) scanning the patient using magnetic resonance imaging to obtain visible images of any diseased tissue or region in the patient.
Claim 5
Dependent Claim
14 words
A method according to claim 1 or 2 wherein the region is the vasculature.
Claim 6
Dependent Claim
15 words
A method according to claim 1 or 2 wherein the region is the cardiovascular region.
Claim 7
Dependent Claim
15 words
A method according to claim 1 or 2 wherein the region is the gastrointestinal region.
Claim 8
Dependent Claim
18 words
A method according to claim 1 or 2 wherein the scanning is of the vasculature of the patient.
Claim 9
Dependent Claim
19 words
A method according to claim 1 or 2 wherein the scanning is of the cardiovascular region of the patient.
Claim 10
Dependent Claim
19 words
A method according to claim 1 or 2 wherein the scanning is of the gastrointestinal region of the patient.
Claim 11
Dependent Claim
35 words
A method according to claim 1 or 2 wherein the scanning is of a region of the patient selected from the following: intranasal tract; auditory canal; intraocular region; intraperitoneal region; kidneys; urethra; and genitourinary tract.
Claim 12
Dependent Claim
11 words
A method of claim 1 wherein said lipid is a phospholipid.
Claim 13
Dependent Claim
11 words
A method of claim 2 wherein said lipid is a phospholipid.
Claim 14
Dependent Claim
11 words
A method of claim 1 wherein said microsphere comprises a monolayer.
Claim 15
Dependent Claim
11 words
A method of claim 12 wherein said monolayer comprises a phospholipid.
Claim 16
Dependent Claim
11 words
A method of claim 2 wherein said microsphere comprises a monolayer.
Claim 17
Dependent Claim
11 words
A method of claim 14 wherein said monolayer comprises a phospholipid.
Claim 18
Dependent Claim
12 words
A method of claim 1 wherein said gaseous precursor is a perfluorocarbon.
Claim 19
Dependent Claim
29 words
A method of claim 11 wherein said gaseous precursor is selected from the group consisting of sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.
Claim 20
Dependent Claim
11 words
A method of claim 17 wherein said gaseous precursor is perfluorohexane.
Claim 21
Dependent Claim
11 words
A method of claim 17 wherein said gaseous precursor is perfluoropropane.
Claim 22
Dependent Claim
21 words
A method of claim 17 wherein said gaseous precursor is selected from the group consisting of perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.
Claim 23
Dependent Claim
11 words
A method of claim 20 wherein said gaseous precursor is perfluoropentane.
Claim 24
Dependent Claim
14 words
A method of claim 1 wherein said microsphere is rehydrated from a lyophilized microsphere.
Claim 25
Dependent Claim
20 words
A method of claim 1 wherein said lipid microsphere comprises at least 70 mole percent of at least one lipid.
Claim 26
Dependent Claim
48 words
A method of claim 1 wherein said lipid microsphere comprises at least two lipids wherein said first lipid contains substantially no linkages to a polymer and comprises at least 70 mole percent of the total moles of the microsphere, and wherein said second lipid bears a hydrophilic polymer.
Claim 27
Dependent Claim
38 words
A method of claim 24 wherein said first lipid comprises: (i) a neutral lipid, and (ii) a negatively charged lipid, wherein the amount of said negatively charged lipid is greater than 1 mole percent of total lipids present.
Claim 28
Dependent Claim
13 words
A method of claim 25 wherein said negatively charged lipid is phosphatidic acid.
Claim 29
Dependent Claim
28 words
A method of claim 24 wherein the hydrophilic polymer of said second lipid is selected from the group consisting of polyethyleneglycol, polypropyleneglycol, polyvinylalcohol, and polyvinylpyrrolidone and copolymers thereof.
Claim 30
Dependent Claim
28 words
A method of claim 24 wherein the lipids comprise about 77.5 mole percent dipalmitoyl-phosphatidylcholine, about 12.5 mole percent of dipalmitoyl-phosphatidic-acid, and about 10 mole percent of dipalmitoylphosphatidylethanolamine-polyethyleneglycol 5000.
Claim 31
Dependent Claim
29 words
A method of claim 24 wherein the lipids comprise about 82 mole percent dipalmitoylphosphatidyl-choline, about 10 mole percent of dipalmitoylphosphatidic acid, and about 8 mole percent of dipalmitoylphosphatidyl-ethanolamine-polyethyleneglycol 5000.
Claim 32
Dependent Claim
12 words
A method of claim 2 wherein said gaseous precursor is a perfluorocarbon.
Claim 33
Dependent Claim
29 words
A method of claim 2 wherein said gaseous precursor is selected from the group consisting of sulfur hexafluoride, perfluoromethane, perfluoroethane, perfluoropropane, perfluorocyclopropane, perfluorobutane, perfluorocyclobutane, perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.
Claim 34
Dependent Claim
11 words
A method of claim 31 wherein said gaseous precursor is perfluorohexane.
Claim 35
Dependent Claim
11 words
A method of claim 31 wherein said gaseous precursor is perfluoropropane.
Claim 36
Dependent Claim
21 words
A method of claim 31 wherein said gaseous precursor is selected from the group consisting of perfluoropentane, perfluorocyclopentane, perfluorohexane, and perfluoroheptane.
Claim 37
Dependent Claim
11 words
A method of claim 31 wherein said gaseous precursor is perfluoropentane.
Claim 38
Dependent Claim
14 words
A method of claim 2 wherein said microsphere is rehydrated from a lyophilized microsphere.
Claim 39
Dependent Claim
20 words
A method of claim 2 wherein said lipid microsphere comprises at least 70 mole percent of at least one lipid.
Claim 40
Dependent Claim
48 words
A method of claim 2 wherein said lipid microsphere comprises at least two lipids wherein said first lipid contains substantially no linkages to a polymer and comprises at least 70 mole percent of the total moles of the microsphere, and wherein said second lipid bears a hydrophilic polymer.
Claim 41
Dependent Claim
38 words
A method of claim 38 wherein said first lipid comprises: (i) a neutral lipid, and (ii) a negatively charged lipid, wherein the amount of said negatively charged lipid is greater than 1 mole percent of total lipids present.
Claim 42
Dependent Claim
13 words
A method of claim 39 wherein said negatively charged lipid is phosphatidic acid.
Claim 43
Dependent Claim
28 words
A method of claim 38 wherein the hydrophilic polymer of said second lipid is selected from the group consisting of polyethyleneglycol, polypropyleneglycol, polyvinylalcohol, and polyvinylpyrrolidone and copolymers thereof.
Claim 44
Dependent Claim
29 words
A method of claim 38 wherein the lipids comprise about 77.5 mole percent dipalmitoyl-phosphatidylcholine, about 12.5 mole percent of dipalmitoyl-phosphatidic acid, and about 10 mole percent of dipalmitoylphosphatidylethanolamine-polyethyleneglycol 5000.
Claim 45
Dependent Claim
29 words
A method of claim 38 wherein the lipids comprise about 82 mole percent dipalmitoylphosphatidyl-choline, about 10 mole percent of dipalmitoylphosphatidic acid, and about 8 mole percent of dipalmitoylphosphatidyl-ethanolamine-polyethyleneglycol 5000.
References Cited (Backward Citations)
US3015128A
Cited
GB1044680A
Cited
US3293114A
Cited
US3594326A
Cited
US3968203A
Cited
US3488714A
Cited
US3615972A
Cited
US3532500A
Cited
US3479811A
Cited
US3732172A
Cited
US3650831A
Cited
US4027007A
Cited
US3873564A
Cited
US4108806A
Cited
US4179546A
Cited
US3960583A
Cited
US4089801A
Cited
US3945956A
Cited
US4138383A
Cited
US4162282A
Cited
US4428924A
Cited
US4229360B1
Cited
US4224179A
Cited
US4229360A
Cited
US4192859A
Cited
US4310506A
Cited
US4276885A
Cited
US4265251A
Cited
US4310505A
Cited
US4342826A
Cited
US4421562A
Cited
US4344929A
Cited
US4315514A
Cited
US4331654A
Cited
US4442843A
Cited
US4681119A
Cited
US4657756A
Cited
US4420442A
Cited
US4533254A
Cited
US4586512A
Cited
US4426330A
Cited
US4534899A
Cited
US4569836A
Cited
US4466442A
Cited
US4540629A
Cited
US4549892A
Cited
EP0107559B1
Cited
US4646756A
Cited
US4603044A
Cited
US4731239A
Cited
US4572203A
Cited
US4718433A
Cited
US4775522A
Cited
US4981692A
Cited
US5141738A
Cited
US4544545A
Cited
US4900540A
Cited
US4615879A
Cited
US5004611A
Cited
US4675310A
Cited
US4728575A
Cited
US4658828A
Cited
US5008050A
Cited
US4620546A
Cited
US4789501A
Cited
US4921706A
Cited
US4830858A
Cited
US4689986A
Cited
US4895719A
Cited
EP0216730B1
Cited
US4684479A
Cited
US4938947A
Cited
US4774958A
Cited
US4987154A
Cited
US4865836A
Cited
US4927623A
Cited
EP0231091B1
Cited
US4737323A
Cited
US4877561A
Cited
EP0243947A1
Cited
US4985550A
Cited
GB2193095A
Cited
US4728578A
Cited
US4776991A
Cited
US4781871A
Cited
US4790891A
Cited
US5195520A
Cited
US5049388A
Cited
US4863717A
Cited
US4933121A
Cited
EP0272091B1
Cited
US4822534A
Cited
US5219538A
Cited
US5000960A
Cited
US5354549A
Cited
US5036003A
Cited
US4844882A
Cited
EP0324938B1
Cited
EP0586875A1
Cited
US5425366A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2002-07-12 | 2003-01-11 | 2003-07-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2006-07-12 | 2007-01-11 | 2007-07-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2010-07-12 | 2011-01-11 | 2011-07-13 | $7700.00 | Window Closed / Lapsed |